Subject no | Sex | Age (years) | FEV1 (% pred) | PC20(mg/ml) | Eosinophils (%) | NO (ppb) |
---|---|---|---|---|---|---|
Steroid treated group | ||||||
1 | M | 24 | 77 | 0.07 | 1.4 | 5.85 |
2 | M | 24 | 104 | 0.37 | 3.8 | 10.75 |
3 | M | 21 | 104 | 0.39 | 5.8 | 11.81 |
4 | F | 23 | 88 | 0.55 | 7.6 | 5.28 |
5 | F | 20 | 83 | 0.71 | 4.0 | 3.42 |
6 | M | 24 | 103 | 0.72 | 0.0 | 8.24 |
7 | M | 23 | 94 | 1.29 | 3.6 | 10.21 |
8 | F | 24 | 101 | 1.81 | 0.2 | 7.25 |
9 | F | 21 | 99 | 2.05 | NA | 2.17 |
10 | M | 28 | 104 | 2.54 | 3.4 | 2.15 |
11 | F | 21 | 98 | 3.14 | 1.4 | 3.92 |
12 | M | 27 | 99 | 3.14 | 0.2 | 4.62 |
23.3 (2.4)1-151 | 96.2 (9.0)1-151 | 0.91 (1.62)1-150 | 2.85 (2.46)1-151 | 6.30 (3.34)1-151 | ||
Placebo group | ||||||
13 | M | 24 | 82 | 0.11 | 21.2 | 13.41 |
14 | F | 21 | 108 | 0.11 | 0.0 | 6.57 |
15 | M | 29 | 111 | 0.14 | 24.6 | 12.05 |
16 | M | 34 | 83 | 0.30 | 0.0 | 4.17 |
17 | M | 21 | 98 | 0.46 | 1.6 | 13.40 |
18 | M | 24 | 80 | 0.54 | NA | 14.08 |
19 | M | 25 | 86 | 0.73 | 0.0 | 3.26 |
20 | M | 24 | 98 | 0.77 | 1.8 | 4.22 |
21 | F | 24 | 106 | 0.89 | 3.2 | 2.48 |
22 | M | 28 | 90 | 1.00 | 1.2 | 3.36 |
23 | F | 28 | 106 | 1.20 | NA | 5.05 |
24 | F | 25 | 98 | 1.51 | 0.0 | 5.82 |
25 | M | 19 | 97 | 1.70 | 0.4 | 9.26 |
25.1 (3.9)1-151 | 95.6 (10.6)1-151 | 0.52 (1.38)1-150 | 4.91 (8.98)1-151 | 7.47 (4.37)1-151 |